Physician profile
Thomas Golubski
NPI 1639176118
$1,453.76
in general payments reported to CMS, 2019-2025
21 companies · $50.28 in 2025
The $50.28 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $31.74 · 2021: $134 · 2022: $289 · 2023: $123 · 2024: $496 · 2025: $50.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $506.17 | 2019-2024 | |
| Fresenius USA Marketing, INC. | $164.73 | 2021-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $113.81 | 2019-2023 | Lokelma |
| Amgen INC. | $107.43 | 2022-2025 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $103.77 | 2019 | |
| Outset Medical INC | $100.82 | 2024 | |
| Vifor Pharma, INC. | $46.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $40.77 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $32.72 | 2019-2023 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $28.69 | 2019 | |
| Ani Pharmaceuticals, INC. | $27.21 | 2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $23.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.98 | 2021 | |
| Akebia Therapeutics INC | $20.62 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.05 | 2021 | |
| Strongbridge US INC. | $17.78 | 2020 | |
| Aurinia Pharma U.S., INC. | $15.58 | 2021 | |
| Glaxosmithkline, LLC. | $15.15 | 2023 | Benlysta |
| Calliditas Therapeutics US INC. | $13.40 | 2024 | |
| Travere Therapeutics, INC. | $11.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Golubski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.